

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/674,624  
Filed: November 3, 2000  
1<sup>st</sup> Inventor: A. Fujishima  
For: Benzimidazole Compound Crystal  
Atty. Dkt. No. 2635 USOP



Art Unit: 1625  
Examiner: J. Fan  
Allowed:  
Batch:  
Paper No.: 6

TECH CENTER 1600/2900

MAR 21 2002

RECEIVED

Supplemental Information Disclosure Statement

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449 under §1.97(c).

No Final Office Action or Notice of Allowance has been mailed in this case.

Applicants herewith authorize the Commissioner to charge the Applicant's USPTO deposit account number 500799 for the appropriate fee as set forth under 37 CFR §1.17(p) for submission of a Supplemental Information Disclosure Statement.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

03/20/2002 ADSMAH1 00000016 500799 09674624  
01 FC:126 180.00 CH

Dated: March 15, 2002

(847) 383-3391  
(847) 383-3372

Elaine M. Ramesh  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Mark Chao, Ph.D., Reg. No. 37,293  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA